[144] Supernus Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 Notice: The filing reports a proposed sale of 4,588 shares of common stock of Supernus Pharmaceuticals, Inc. (SUPN) through Morgan Stanley Smith Barney, with an aggregate market value of $205,909.44. The shares represent part of a holding originally acquired on 05/01/2012 as an in-kind distribution from NEA Partners.

The filer for whose account sales are reported is identified as Charles Newhall, who also sold 1,412 shares on 08/22/2025 for gross proceeds of $63,543.95. The issuer's total shares outstanding are listed as 56,073,088. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Small insider sale relative to shares outstanding; not likely material to SUPN's valuation.

The filing shows a planned sale of 4,588 common shares valued at $205,909.44 and a recent 10b5-1 sale of 1,412 shares for $63,543.95. Given the issuer's reported 56,073,088 shares outstanding, the transaction size is trivial as a percentage of the float. The acquisition origin (in-kind distribution from NEA Partners in 2012) is disclosed, which is relevant for lock-up/holding-period context. There is no new operational or financial information in the notice; it is a standard reporting of intended insider dispositions.

Corporate Governance Expert

TL;DR: Routine insider disclosure consistent with Rule 144; includes representation about nonpublic material information.

The notice follows Rule 144 disclosure conventions and names the broker and planned sale date. The seller attests not to possess undisclosed material adverse information, and the filing references prior 10b5-1 sales activity. From a governance standpoint, this is a compliance disclosure rather than a signal of corporate change. No departures, new plans, or control transactions are reported.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4588	205909.44	56073088	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2012	In-Kind Distribution	NEA Partners			4588	05/01/2012	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CHARLES NEWHALL 9715 Key West Avenue Rockville MD 20850	Common	08/22/2025	1412	63543.95

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What securities does the SUPN Form 144 report propose to sell?

The notice proposes to sell 4,588 common shares of Supernus Pharmaceuticals (SUPN) through Morgan Stanley Smith Barney.

What is the aggregate market value of the shares to be sold under the SUPN Form 144?

The filing lists an aggregate market value of $205,909.44 for the 4,588 shares.

Who is the person for whose account the SUPN securities are being sold?

The filing identifies the seller as Charles Newhall, with prior 10b5-1 sales of 1,412 shares on 08/22/2025 for $63,543.95.

How were the shares being sold originally acquired?

The 4,588 shares were acquired on 05/01/2012 as an in-kind distribution from NEA Partners.

Does the Form 144 indicate any undisclosed material information about SUPN?

No. By signing the notice, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.